Over 6 billion large varieties!

A few days ago, Hefei Lifang Pharmaceutical entered the administrative examination and approval stage with generic 4 types of Nifedipine Controlled Release Tablets
.
According to data from Mi Nei.
com, the total sales of this product in China's public medical institutions and physical pharmacies in Chinese cities will exceed 6 billion yuan in 2020.
Bayer dominates the market, but its market share is declining
.
Source: The official website of the State Drug Administration.
Nifedipine is a dihydropyridine calcium antagonist, which can selectively inhibit the transmembrane transport of calcium ions into cardiomyocytes and smooth muscle cells, and inhibit the release of calcium ions from the intracellular pool without changing plasma Calcium ion concentration, clinically used to treat hypertension and angina pectoris
.
Including Bayer, five domestic companies have production approvals for nifedipine controlled-release tablets.
According to data from Meinenet, the product will be used in urban public hospitals, county-level public hospitals, urban community centers, and township health centers in China in 2020.
The combined sales of public medical institutions and physical pharmacies in cities in China exceeded 6 billion yuan, an increase of approximately 8% year-on-year
.
In recent years, nifedipine controlled-release tablets have continued to increase their volume in public medical institutions in China.
In 2021, the H1 sales growth rate exceeded 30%, ranking fifth among the top 10 chemical drugs, up 5 places from 2020
.
From the perspective of the competitive landscape of manufacturers, the original research manufacturer Bayer dominates the market, but its market share is declining year by year due to the influence of generic drugs
.
At present, only Shanghai Modern Pharmaceutical has submitted a supplementary application for the consistency evaluation of nifedipine controlled-release tablets, which is still under review and approval; in addition, 11 companies have submitted applications for the product’s listing under the new registration classification, including Qingdao Baiyang Pharmaceutical and Hainan Simcere The products of the three companies in the industry and Nanjing Yiheng Pharmaceutical have been approved for production and deemed to have been reviewed
.
New classification of nifedipine controlled-release tablets.
Source: Menet.
com MED2.
0 Chinese Drug Evaluation Database Among other companies, Hefei Lifang Pharmaceutical’s nifedipine controlled-release tablets have entered the administrative approval stage and become the fifth domestic company
.
According to data from Minaiwang, only one product of Hefei Lifang Pharmaceutical has been reviewed, which is trimetazidine hydrochloride sustained-release tablets.
Nifedipine controlled-release tablets are expected to become the company's second reviewed product.

.
Source: Meinenet database, official website of the State Food and Drug Administration, etc.
Note: Meinenet China's urban entity pharmacy terminal competition pattern database covers 293 prefectures and above cities across the country (excluding county and rural entity pharmacies), continuous for all categories Monitored enlarged version of the city's physical pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of November 24.
If there are any omissions, please correct me!